Despite the rapidly increasing prevalence and associated costs of obesity, treatment options have remained remarkably limited. Some 650 million people are estimated to be living with but until recently lipase inhibitor orlistat was only mainstay pharmacological option, alongside dietary restriction. However, FDA approval glucagon-like peptide 1 receptor (GLP-1R) agonists, liraglutide semaglutid...

OBJECTIVE We have developed a novel platform for display and delivery of bioactive peptides that links the biological properties of the peptide to the pharmacokinetic properties of an antibody. Peptides engineered in the MIMETIBODY platform have improved biochemical and biophysical properties that are quite distinct from those of Fc-fusion proteins. CNTO736 is a glucagon-like peptide 1 (GLP-1) ...

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases in industrialized countries, with approximately 30%-40% of adults suffering from NAFLD. Of those, 15%-20% will develop to its progressive entity nonalcoholic steatohepatitis (NASH), a condition that may further progress to liver fibrosis and cirrhosis. Because insulin resistance and visceral obesity are major c...